Compare LIXT & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LIXT | GROW |
|---|---|---|
| Founded | 2005 | 1968 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5M | 31.3M |
| IPO Year | N/A | 1995 |
| Metric | LIXT | GROW |
|---|---|---|
| Price | $3.56 | $2.59 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 37.1K | 34.8K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 3.37% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $23,850,609.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $51.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $2.09 |
| 52 Week High | $6.09 | $3.65 |
| Indicator | LIXT | GROW |
|---|---|---|
| Relative Strength Index (RSI) | 58.16 | 45.78 |
| Support Level | $2.50 | $2.35 |
| Resistance Level | $4.45 | $2.83 |
| Average True Range (ATR) | 0.28 | 0.14 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 62.24 | 36.90 |
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.